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Abstract 
The recent public health crisis is threatening the world with the emergence of the spread of the new 
coronavirus 2019 (2019-nCoV) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 
This virus originates from bats and is transmitted to humans through unknown intermediate animals 
in Wuhan, China in December 2019. Advances in technology have opened opportunities to find 
candidates for natural compounds capable of preventing and controlling COVID-19 infection through 
inhibition of spike proteins of SARS-CoV-2. This research aims to identify, evaluate, and explore the 
structure of spike protein macromolecules from three coronaviruses (SARS-CoV, MERS-CoV, and 
SARS-CoV-2) and their effects on Angiotensin-Converting Enzyme 2 (ACE-2) using computational 
studies. Based on the identification of the three spike protein macromolecules, it was found that there 
was a similarity between the active binding sites of ACE-2. These observations were then confirmed 
using a protein-docking simulation to observe the interaction of the protein spike to the active site of 
ACE-2. SARS-COV-2 spike protein has the strongest bond to ACE-2, with an ACE score of −1341.85 
kJ/mol. Therefore, some of this information from the results of this research can be used as a reference 
in the development of competitive inhibitor candidates for SARS-CoV-2 spike proteins for the 
treatment of COVID-19 infectious diseases. 
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The 2019 novel coronavirus (COVID-19) 
infectious disease caused by severe acute 
respiratory syndrome coronavirus (SARS-CoV-
2) continues to spread from its origins in Wuhan 
City, Hubei Province, China to the rest of the 
world [1]. Till 10/04/2020 there are 
approximately 1.6 million cases in 2019 
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coronavirus (COVID-19), with 95.604 deaths 
and 355.671 recovered [2]. Indonesia has 
reported 4,241 cases to date. Because 
knowledge of this coronavirus is developing 
rapidly, researchers need to identify the 
characteristics of SARS-CoV-2 [3]. Thus, 
effective drug candidates for the prevention and 
control of this infectious disease can be found. 
Coronavirus is a positive sensory RNA 
virus with diameters ranging from 60 nm to 140 
nm belonging to the Coronaviridae family [4,5]. 
In general, this virus can cause mild respiratory 
infections in humans [6]. Several other 
coronavirus infections have previously caused 
deadly endemics, including SARS (Severe Acute 
Respiratory Syndrome) and MERS (Middle East 
Respiratory Syndrome) [7]. Both diseases are 
caused by zoonotic coronaviruses which belong 
to the genus Betacoronavirus in Coronaviridae 
[8]. SARS-CoV originated in southern China and 
was endemic in 2003, while MERS first occurred 
in Saudi Arabia in 2012. 
Like SARS-CoV and MERS-CoV, SARS-CoV-
2 has a genome size of about 30 kilobases which 
functions to encode several structural proteins, 
including spike protein (S), an envelope protein 
(E), membrane protein (M), and nucleocapsid 
protein (N) [9]. Preliminary studies also show 
that SARS-CoV-2 is identical to SARS-CoV based 
on the complete phylogenetic analysis of 
genomes. Because of the apparent similarity 
between the two viruses, it is necessary to 
further explore the constituent components of 
one structural protein, such as the spike protein 
from SARS-CoV and SARS-CoV-2 [10,11]. 
The entry of SARS-CoV-2 into cells is 
mediated by spike proteins found on the surface 
of the coronavirus and binds to Angiotensin-
Converting Enzyme 2 (ACE-2) to infect host 
cells. SARS-CoV-2 involves ACE-2 with an 
affinity that is comparable to SARS-CoV and 
MERS-CoV [12]. A tight bond on ACE-2 can 
explain part of the efficient transmission of 
SARS-CoV-2 in humans, as happens in SARS-CoV 
and MERS-CoV [13,14]. Inhibition of the 
attachment of spike proteins from SARS-CoV-2 
with ACE-2 can prevent COVID-19 infection. 
Until now, the need to design effective 
antivirus candidates against SARS-CoV-2 has 
increased. This study aims to identify, evaluate, 
and explore the structure of spike protein 
macromolecules from SARS-CoV, MERS-CoV, 
and SARS-CoV-2, and their effects in inhibiting 
binding with ACE-2. Computational studies can 
be used to observe potential components of this 
coronavirus [15]. Specifically, the SARS-CoV-2 
protein spike is considered a target because it is 
a major part of forming coronavirus 
characteristics. Therefore, through this 
research, information is expected to be used as 
a reference in the development of drug 
compounds for COVID-19 infectious diseases.  
 
2 Materials and Methods  
2.1 Spike Proteins Preparation 
Macromolecules used in this study were 
the spike proteins of coronavirus (SARS-CoV, 
MERS-CoV, and SARS-CoV-2) obtained from 
Protein Data Bank (http://www.rcsb.org/pdb) 
with PDB ID 6NB6 [16], 5X5C [17], and 6VYB 
[18], respectively. The preparation of these 
three macromolecules was performed by 
removing water molecules and natural ligands 
using BIOVIA Discovery Studio 2020 [19]. 
2.2 Analysis of Three-Dimensional 
Conformation Spike Proteins 
Spike protein macromolecules from SARS-
CoV, MERS-CoV, and SARS-CoV-2 which were 
prepared then overlapped three-dimensional 
conformations with a representation of 
secondary structures to identify similarities and 
observe differences from the macromolecules of 
the two protein spikes. This process was 
performed using BIOVIA Discovery Studio 2020 
[19] and Chimera 1.14 [20]. 
2.3 Identification of Spike Proteins 
Sequencing 
Further identification was accomplished 
for sequencing of the SARS-CoV, MERS-CoV, and 
SARS-CoV-2 protein spike macromolecules 
using BIOVIA Discovery Studio 2020 [19] and 
Notepad++. Amino acid residues that play a role 
in the structure of spike protein 
macromolecules are then evaluated and 
explored. 
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2.4 Angiotensin-Converting Enzyme (ACE-2) 
Preparation 
Macromolecules Angiotensin-Converting 
Enzyme (ACE-2) used in this study were 
obtained from Protein Data Bank 
(http://www.rcsb.org/pdb) with PDB ID 2AJF 
[21]. The preparation of this macromolecules 
was performed by removing natural ligands and 
water molecules using BIOVIA Discovery Studio 
2020 [19]. 
2.5 Effect of Spike Protein Complexes 
against ACE-2 Binding 
This simulation was accomplished 
between spike proteins of SARS-CoV, MERS-
CoV, and SARS-CoV-2 against Angiotensin-
Converting Enzyme (ACE-2) macromolecule. 
Complex types were selected as proteins with 
default clustering RMSD 4.0 Å. The 
representation of the Connolly dot surface of the 
molecule into different components including 
convex, concave, and flat patch was generated 
through the PatchDock algorithm [22]. 
PatchDock was optimized, refined, overhauled, 
and reselected the side chain interface from the 
top 10 candidate solutions. It also changes the 
orientation of the molecule relative by limiting 
flexibility in the side chains of the interacting 
surface and allowing the movements of small 
rigid-body. The suitability of the system was 
verified by visualization analysis using BIOVIA 
Discovery Studio 2020 [19].  
3 Results and Discussion 
The introduction of receptor 
macromolecular structures is the first step in 
recognizing the mechanism of viral infection 
against host cells and tissues. Increased binding 
affinity between the SARS-CoV spike protein 
and ACE-2 has been shown to correlate with 
increased virus transmission and disease 
severity in humans. In addition, the ability to 
involve ACE-2 from different animal species 
seems to reflect the host's susceptibility to 
SARS-CoV infection and facilitate the leap of 
viruses from animals to humans. SARS-CoV-2 
uses ACE-2 as an entry receptor and recognizes 
it with an affinity similar to SARS-CoV and 
MERS-CoV. 
In this study was performed identification, 
evaluation, and exploration of spike protein 
macromolecules from SARS-CoV, MERS-CoV, 
and SARS-CoV-2 to observe the structural 
characteristics of its components through 
computational study. Moreover, observations 
were also performed on the interactions 
between three spike proteins with ACE-2. 
Macromolecules that will be used in this study 
were prepared by removing water molecules 
and natural ligands using the BIOVIA Discovery 
Studio 2020. Macromolecular preparation was 








            
◼ SARS-CoV   ◼ MERS-CoV  ◼ SARS-CoV-2 
Figure 1. The three-dimensional conformation spike proteins overlay of (A) SARS-CoV against SARS-CoV-2 and (B) MERS-CoV 
against SARS-CoV-2  
B A 
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Figure 2. The sequence of ACE-2 receptor binding domain (RBD) on the spike proteins of SARS-CoV (green), MERS-CoV (blue), 




Representations of spike protein 
macromolecules were visualized in the form of 
secondary structures to identify alpha-helix, 
beta-sheet, and loop sections as a whole. Figure 
1 show that the protein spikes of SARS-CoV and 
SARS-CoV-2 have significant similarities. 
However, when compared to MERS-CoV, there 
are some differences, including the two sections 
located at the top (in the red box sections). Then 
the alpha-helix at the bottom of the SARS-CoV-2 
spike protein macromolecule. This needs to be 
further proven by exploring the amino acid 
residues that make up the three spike protein 
macromolecules. 
Interestingly, the sequences from the ACE-
2 binding site of all spike proteins are relatively 
identical (Figure 2). The active site of SARS-CoV-
2 was less that is only 180 amino acid residues 
compared to SARS-CoV and MERS-CoV. This 
phenomenon can be predicted that the protein 
spikes of SARS-CoV and MERS-CoV will bind 
more strongly on the surface of ACE-2. 
Nevertheless, the amino acid residue 
component forming receptor-binding domain 
(RBD) from SARS-CoV and SARS-CoV-2 have in 
common (in the yellow sections). There are 31 
amino acid residues play an important role as 
RBD SARS-CoV and SARS-CoV-2, such as 
Cys336, Pro337, Phe338, Gly339, Glu340, 
Val341, Phe342, Asn343, Ala344, Thr345, 
Arg346, Phe347, Ala348, Ser349, Val350, 
Tyr351, Ala352, Trp353, Gly504, Tyr505, 
Gln506, Pro507, Tyr508, Arg509, Val510, 
Val511, Val512, Leu513, Ser514, Phe515, and 
Glu516. While MERS-CoV only 5 amino acid 
residues, including Cys336, Pro337, Ser514, 
Phe515, and Glu516. 
Further identification was performed 
through the protein-protein docking methods. 
The binding affinity of ACE-2 against each spike 
proteins was evaluated by the atomic contact 
energy (ACE) score integrated into the 
PatchDock algorithm. The purpose of this 
docking simulations was to examine the effect of 
the active binding sites of spike proteins on the 
surface of ACE-2. The large area of RBD in spike 
proteins is predicted to be able to facilitate the 
entry of coronavirus into cells because of the 
ability of SARS-CoV, MERS-CoV, and SARS-CoV-
2 to reach ACE-2 and forward the signal. 
Therefore, it is also necessary to explore amino 
acid residues that play a role in the formation of 
molecular interactions between the spike 




Table 1. The affinity of each spike proteins against ACE-2 







The results of the protein-protein docking 
simulations in Table 1 show that all three 
protein-protein complexes have a negative ACE 
score. This phenomenon can be caused by 
molecular interactions that form between spike 
proteins and ACE-2, both hydrogen bonds, 
hydrophobic interactions, and electrostatic 
interactions. Interestingly, the spike protein of 
SARS-CoV-2 was able to bind strongly to the 
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surface of ACE-2 macromolecules with an ACE 
score of −1341.85 kJ/mol. In designing an 
inhibitor for COVID-19, a natural compound that 
can inhibit SARS-CoV-2 is not easily bound to 
the active site of ACE-2, and stabilizes the 
structure of the receptor macromolecules and 
prevents the conformational changes needed to 
forward signals further. 
Interactions between SARS-CoV-2 and 
ACE-2 consist of 16 hydrogen bonds (with 
Arg440, Tyr450, Pro476, Asp477, Asn487, 
Tyr489, Tyr495, Gly496, Tyr498, Gly502, and 
Tyr505), 7 hydrophobic interactions (with 
Tyr454, Leu486, Tyr489, Tyr498, and Tyr505), 
and 3 electrostatic interactions (with Arg440 
and Asp441). Moreover, the molecular 
interactions that were formed are dominated by 
hydrogen bonds, especially those that act as 
donor hydrogen bonds and hydrogen bond 
acceptors. Most hydrogen bonds between these 
proteins are quite strong, with average bond 
lengths under 3 Å. In addition, there are also 
hydrophobic interactions and electrostatic 
interactions that contribute. It can be predicted 
that these bonds and interactions play an 





Figure 3. Protein-protein docking pose of SARS-CoV-2 




Overall, it can be shown that the spike 
protein of SARS-CoV-2 binds to the non-polar 
patch of the ACE-2 surface (Figure 3). In 
developing COVID-19 inhibitor compounds, a 
candidate molecule that can prevent the 




Based on research that has been done, the 
results show that there are some similarities 
between the structures of the spike protein 
macromolecules of several coronaviruses. 
SARS-CoV-2 spike protein has a fairly strong 
interaction with the binding site of ACE-2, with 
an ACE score of −1341.85 kJ/mol. Therefore, 
natural compounds that act as SARS-CoV-2 
spike protein inhibitors are needed for the 
development of candidate molecules that can 
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